Bringing the fundamentals into focus…
Back to Taysha Gene Therapies, Inc.
How Taysha Gene Therapies, Inc. stacks up
TSHA · against 453 other Healthcare companies of similar size
Valuation
8/ 100
Near the bottom of its peers.
Ranked #322 of 454 · scores higher than 9% of peers
Bars: peers in each 10-point band of the valuation score133 peers with a valuation score of 0–9, including TSHA · Click a bar to see the companies
Why valuation scores 8?
Weighted metrics compared with all Healthcare companies.Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. EBITDA yield: -16.3% vs peer median 4.0%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -10.0% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -10.2% vs peer median 0.0%
Metric by metric
Position: dot = TSHA, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | TSHA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 444 reported | -10.0% | 1.5% | 16% | 30% | |
| EBITDA yieldHigher is better · 459 reported | -16.3% | 4.5% | 10% | 50% | |
| Free cash flow yieldHigher is better · 203 reported | -10.2% | -1.2% | 21% | 20% | |
| Book yieldHigher is better · 449 reported | 18.0% | 40.0% | 21% | Context only |
Ranking by valuation score
Top 5 and the companies ranked around TSHA| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 40.2B MXN (≈$2.2B) | 99 | 71 | |
| 1 | 14.8B MXN (≈$800M) | 99 | 61 | |
| 322 | 976M USD | 8 | 36 | |
| 322 | 1.2B USD | 8 | 24 | |
| 322 | 2.2B USD | 8 | 23 | |
| 322 | 2.0B USD | 8 | 42 | |
| 322 | 1.3B USD | 8 | 44 | |
| 322 | 1.5B USD | 8 | 39 | |
| 322 | 1.7B USD | 8 | 31 | |
| 322 | 2.2B USD | 8 | 35 | |
| 322 | 1.9B USD | 8 | 42 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score